Tumor Exosome Liquid Biopsy Strategy to Diagnose Pancreatic Cancer

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is an observational study of patients diagnosed with pancreatic cancer by pathology, with a control group of patients with pathology suggestive of benign pancreatic lesions and normal subjects, and the diagnostic ability of exosomes to identify patients with pancreatic cancer was assessed through the detection of exosomes in the peripheral blood.

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT01078662` - Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats	Phase 2

NCT number	NCT06108531
Study type	Observational
Source	Shanghai Jiao Tong University School of Medicine
Contact
Status	Enrolling by invitation
Phase
Start date	November 1, 2023
Completion date	August 1, 2026

Tumor Exosome Liquid Biopsy Strategy to Diagnose Pancreatic Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms